Global HPV vaccine coverage is recovering and has surpassed pre-pandemic levels but remains below the 2030 cervical cancer elimination goal. Coverage in Low- and Middle-Income Countries (L/MICs) has improved but remains below 2019 levels. Improvements in coverage are due to new introductions in L/MICs and resumption of programmes interrupted by COVID or supply challenges.

- Gavi supported and transitioned countries:
  - Routine introductions: 20 countries
  - Routine plus multi-age cohort (MAC): 11 countries
  - Approved, pending introduction: 7 countries

- Middle Income Countries (MICs): 16 countries are procuring through UNICEF.

Supply forecast includes demand for Gavi supported and transitioned countries, Gavi MICs and other MICs procuring through UNICEF.

Demand forecast assumes that Gavi supported and transitioned countries will transition to 1-dose schedule by 2025.

Demand forecast peaks in 2024 and 2025 due to delayed MACs in 9 countries and introduction in India (Gavi Catalytic Support).

Supply availability is improving, needs careful planning in 2024 and is anticipated to exceed demand in 2025 depending on product preference.

Additional awards are anticipated to be made for 2024/2025 depending on timing of forecasted introductions.

Annual procurement volumes have increased yearly from 2013 except in 2022 where there were delays in country introductions and sufficient stock on hand in countries due to low coverage during the COVID period.